Therapy Areas: AIDS & HIV
ViiV Healthcare Presents Positive Five-Year Data at AIDS 2022, Showing the Durability of Fostemsavir in People Living with HIV Who Are Heavily Treatment-Experienced
29 July 2022 - - UK-based ViiV Healthcare, the global specialist HIV company majority owned by British pharmaceutical company GSK (NYSE: GSK), with US-based Pfizer (NYSE: PFE) and Japan-based Shionogi (OTC: SGIOY) as shareholders, has released week 240 results from the phase III BRIGHTE study of fostemsavir in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection who have very few treatment options left available to them due to resistance, intolerance, or other safety concerns, the company said.

The BRIGHTE study is an international, two-cohort (randomised and non-randomised), phase III clinical trial evaluating the safety and efficacy of fostemsavir, a first-in-class attachment inhibitor, used in combination with optimised background treatment in 371 patients from 113 sites across 22 countries.

Study findings showed that people living with multidrug-resistant HIV-1 treated for approximately five years with fostemsavir-based regimens experienced durable virologic responses and continued clinically meaningful improvements in CD4+ cell count and CD4+/CD8+ ratio.

These findings were shared TODAY during the 24th International AIDS Conference (AIDS 2022) in Montreal, Canada.

In the randomised cohort, rates of virologic response generally remained consistent over time through week 240, with 45% (120/272) of patients receiving fostemsavir plus OBT in the randomised cohort achieving virologic suppression (HIV-1 RNA


Related Headlines